



01/16/98

EXPRESS MAIL NO.: EM061 035 581US

PATENT

# 6/3/98

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Cameron et al.

Serial No.: 08/747,122

Group Art Unit: 1811

Filed: November 8, 1996

Examiner: P. Touzeau

For: METHODS OF TREATING  
DISEASE USING SERTOLI  
CELLS AND ALLOGRAFTS OR  
XENOGRAFTS

Attorney Docket No.: 8661-009

RESPONSE TO RESTRICTION REQUIREMENT  
UNDER 37 C.F.R. § 121

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

FEB 02 1998

GROUP 1800

Sir:

In response to the Restriction Requirement dated September 26, 1997, please consider the following remarks. Applicants herein elect to prosecute the claims of Group I (Claims 1-33), drawn to a method of treating a disease that results from a deficiency of a biological factor in a mammal, comprising administering sertoli cells and a therapeutically effective amount of cells that produce the biological factor, without prejudice to the Applicant's right to pursue the subject matter of the non-elected claims in other applications.

Applicants respectfully request that the above-made remarks be made of record in the file history of the instant application.

It is estimated that no fee is required for this response. In the event that a fee is required, please charge the fee to Pennie & Edmonds Deposit Account No. 16-1150.

Respectfully submitted,

*By Carmella L. Stephens*

*Reg. No. 41,328*

Date January 16, 1998

Brian M. Poissant 30,742  
Brian M. Poissant (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090